Q1 Company News Roundup with Wall Street Analyst Kyle Mikson

<p>What kind of market share can Illumina expect when it launches its own MRD kits and is it worth the risk of annoying customers that also offer those tests? </p><p>Why did liquid biopsy company stocks do so well in May?</p><p>What were his headline takeaways from the recent American Society of Clinical Oncology annual meeting?</p><p>Where is he going on summer vacation after a hectic several months?</p><p>Tune in to hear the answers to these questions, and more.</p><p></p><p>If you’re interested in learning more about Kyle’s takes on the life science tools and diagnostics industries, you can reach out to him on LinkedIn to start a conversation. </p><p></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/kylemiksoncfa/" target="_blank">https://www.linkedin.com/in/kylemiksoncfa/</a></p><p></p><p>For full disclosure, he asked me to note that Seer is an investment banking client of Canaccord Genuity.</p>